<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="712">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151382</url>
  </required_header>
  <id_info>
    <org_study_id>SED-AD</org_study_id>
    <secondary_id>SED-AD-2016-001</secondary_id>
    <nct_id>NCT03151382</nct_id>
  </id_info>
  <brief_title>A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease</brief_title>
  <official_title>A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Provincial People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: Evaluation the improvement of the cognitive function of tandospirone add-on&#xD;
      treatment on patients with AD comorbid anxiety.&#xD;
&#xD;
      Number of Patients: 30&#xD;
&#xD;
      Methodology: Randomized, open-label, parallel-group&#xD;
&#xD;
      Assigned Interventions: Experimental: Tandospirone, 30-60 mg/d + Donepezil, 10 mg/d; Control&#xD;
      group: Donepezil, 10 mg/d.&#xD;
&#xD;
      Effect Evaluation: Primary Outcome: Change from baseline in ADAS-cog total score at week 12;&#xD;
      NPI scale total score at week 12;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">May 20, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of ADAS-cog total score</measure>
    <time_frame>week 12</time_frame>
    <description>Change from baseline in ADAS-cog total score at week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NPI scale total score</measure>
    <time_frame>week 12</time_frame>
    <description>NPI scale total score at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAMA total score</measure>
    <time_frame>week 12</time_frame>
    <description>HAMA total score at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FAB score</measure>
    <time_frame>week 12</time_frame>
    <description>FAB score at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative power</measure>
    <time_frame>week 12</time_frame>
    <description>Change from baseline in the relative power at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the image of PET</measure>
    <time_frame>week 12</time_frame>
    <description>the image of PET at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMSE score</measure>
    <time_frame>week 12</time_frame>
    <description>MMSE score at week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Function</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tandospirone Citrate</intervention_name>
    <description>Tandospirone, 30-60 mg/d</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil Hydrochloride</intervention_name>
    <description>Donepezil, 10 mg/d</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  55-80 years old (including 55 and 80), male or female, sufficient vision, hearing and&#xD;
             general health to complete the follow-up and assessment;&#xD;
&#xD;
          -  Patients who were diagnosed with AD according to the DSM-IV;&#xD;
&#xD;
          -  MMSE score &gt; 10 and ≤ 24;&#xD;
&#xD;
          -  HAMA score &gt; 8;&#xD;
&#xD;
          -  HAMD score ≤ 7;&#xD;
&#xD;
          -  Brain CT or MRI supports the diagnosis of AD;&#xD;
&#xD;
          -  Provide written informed consent by the patient himself and his family member or&#xD;
             guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia from any other cause;&#xD;
&#xD;
          -  Brain MRI showed that the diameter of hyperintense lesions in T2-FLAIR sequences were&#xD;
             larger than 5mm;&#xD;
&#xD;
          -  Patients with significant cardiac, pulmonary, hepatic, renal, or hematologic disease;&#xD;
&#xD;
          -  Any primary neurologic or psychiatric disease other than AD;&#xD;
&#xD;
          -  Mental disorders due to substance abuse;&#xD;
&#xD;
          -  Participation in other clinical studies within the last 30 days;&#xD;
&#xD;
          -  History of alcohol or substance abuse or dependence within the past year;&#xD;
&#xD;
          -  Pregnant or breastfeeding, or of child-bearing potential during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Enyan Yu</investigator_full_name>
    <investigator_title>Secretary of Party Committee</investigator_title>
  </responsible_party>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Cognitive Function</keyword>
  <keyword>tandospirone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tandospirone</mesh_term>
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

